CompletedPhase 1

A Clinical Study of Calderasib (MK-1084) With Rosuvastatin and Metformin in Healthy People (MK-1084-016)

United States16 participantsStarted 2025-11-19

Plain-language summary

Researchers want to learn about calderasib when given with rosuvastatin and metformin in healthy people. The goal of this study is to compare the amount of rosuvastatin and metformin in a person's body over time when given with and without calderasib

Who can participate

Age range19 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: \- Has body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m\^2 Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has history of cancer (malignancy) * Positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV)

What they're measuring

Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Rosuvastatin

Timeframe: Day 1: Predose and at designated timepoints up to 120 hours post-dose

Maximum Plasma Concentration (Cmax) of Rosuvastatin

Timeframe: Day 1: Predose and at designated timepoints up to 120 hours post-dose

AUC0-inf of Metformin

Timeframe: Day 1: Predose and at designated timepoints up to 72 hours post-dose

Trial details

NCT IDNCT07222098

SponsorMerck Sharp & Dohme LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-12-14

View on ClinicalTrials.gov More Healthy trials